BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23816498)

  • 1. Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).
    Jaeger T; Andres C; Grosber M; Zirbs M; Hein R; Ring J; Traidl-Hoffmann C
    Eur J Dermatol; 2013; 23(3):408-10. PubMed ID: 23816498
    [No Abstract]   [Full Text] [Related]  

  • 2. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
    Groleau PF; Grossberg AL; Gaspari AA
    Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature].
    García-Rabasco AE; Esteve-Martínez A; Zaragoza-Ninet V; Sánchez-Carazo JL; Alegre-de-Miquel V
    Actas Dermosifiliogr; 2010 Oct; 101(8):717-21. PubMed ID: 20965015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
    Bruzzese V
    J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
    Reddick CL; Singh MN; Chalmers RJ
    Dermatol Online J; 2010 Aug; 16(8):15. PubMed ID: 20804692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
    Shenefelt PD
    Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients.
    Join-Lambert O; Duchatelet S; Delage M; Miskinyte S; Coignard H; Lemarchand N; Alemy-Carreau M; Lortholary O; Nassif X; Hovnanian A; Nassif A
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S66-9. PubMed ID: 26470620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyoderma gangrenosum associated with hidradenitis suppurativa.
    Ah-Weng A; Langtry JA; Velangi S; Evans CD; Douglas WS
    Clin Exp Dermatol; 2005 Nov; 30(6):669-71. PubMed ID: 16197385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy.
    Koshelev MV; Garrison PA; Wright TS
    Pediatr Dermatol; 2014; 31(1):e20-1. PubMed ID: 24118007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.
    Hsiao JL; Antaya RJ; Berger T; Maurer T; Shinkai K; Leslie KS
    Arch Dermatol; 2010 Nov; 146(11):1265-70. PubMed ID: 21079064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases.
    Moschella SL
    Int J Dermatol; 2007 Dec; 46(12):1287-91. PubMed ID: 18173525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?
    Zivanovic D; Masirevic I; Ruzicka T; Braun-Falco M; Nikolic M
    Australas J Dermatol; 2017 May; 58(2):e54-e59. PubMed ID: 26831949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target.
    Kok Y; Nicolopoulos J; Varigos G; Howard A; Dolianitis C
    Australas J Dermatol; 2020 Aug; 61(3):e373-e374. PubMed ID: 32285437
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
    Vinkel C; Thomsen SF
    Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin-responsive hidradenitis suppurativa.
    Buckley DA; Rogers S
    J R Soc Med; 1995 May; 88(5):289P-290P. PubMed ID: 7636825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
    Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
    J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
    [No Abstract]   [Full Text] [Related]  

  • 17. Pyoderma gangrenosum, acne, hidradenitis suppurativa syndrome associated with type 1 diabetes mellitus treated with adalimumab.
    Fattore D; Pistone G; Bongiorno MR
    G Ital Dermatol Venereol; 2019 Apr; 154(2):218-220. PubMed ID: 29368847
    [No Abstract]   [Full Text] [Related]  

  • 18. Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline.
    Gul MI; Singam V; Hanson C; Neill BC; Aires DJ; Rajpara AN
    J Drugs Dermatol; 2020 Nov; 19(11):1123. PubMed ID: 33196740
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review.
    Wang LL; Micheletti RG
    J Am Acad Dermatol; 2020 Feb; 82(2):507-510. PubMed ID: 31541746
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
    Sun NZ; Ro T; Jolly P; Sayed CJ
    J Clin Aesthet Dermatol; 2017 Sep; 10(9):36-38. PubMed ID: 29344326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.